Astellas Pharma Inc. (ALPMF)
Chart Events
Performance Outlook
| Previous Close | 15.53 |
| Open | 15.53 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 15.53 - 15.53 |
| 52 Week Range | 14.56 - 17.95 |
| Volume | |
| Avg. Volume | 1,056 |
| Market Cap | 29.728B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 27.78 |
| EPS (TTM) | 0.56 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.47 (3.11%) |
| Ex-Dividend Date | Sep 29, 2022 |
| 1y Target Est | N/A |
- PR Newswire
Astellas Announces Management Structure
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the following changes to its management structure effective October 1, 2022.
- Investor's Business Daily
Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?
Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.
- Benzinga
Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say
Earlier today, Seagen Inc (NASDAQ: FBI) and Astellas Pharma Inc (OTC: ALPMF) announced topline results from the phase 1b/2 EV-103 trial (KEYNOTE-869) cohort K of Padcev (enfortumab vedotin-ejfv) in metastatic urothelial carcinoma (mUC). Needham says that the results from Cohort K primarily live up to expectations. The management has previously indicated that results from Cohort K could be used to support accelerated approval in the 1L cis-ineligible mUC setting. See the Seagen Analyst Page here.
